Sanofi completes the acquisition of Protein Sciences
(Thomson Reuters ONE) -
Sanofi completes the acquisition of Protein Sciences
- An innovative quadrivalent influenza vaccine
will complement Sanofi Pasteur vaccine portfolio -
Paris, France - August 28, 2017 - Sanofi announced today that it has completed
the acquisition of Protein Sciences, a vaccines biotechnology company based in
Meriden, Connecticut in the United States. This completion follows Federal Trade
Commission approval, having met all the conditions required for the closing of
the transaction.
Through the acquisition, Sanofi Pasteur, the vaccines global business unit of
Sanofi, adds a promising product to its influenza vaccine portfolio: Flublok(®)
(Influenza Vaccine), the only recombinant protein-based influenza vaccine
approved by the US Food and Drug Administration (FDA). In October 2016, Protein
Sciences received approval from the FDA for the quadrivalent version of Flublok
vaccine (Flublok Quadrivalent vaccine), indicated for adults 18 years and older.
"We are thrilled to welcome the talented employees and assets of Protein
Sciences within Sanofi Pasteur," said David Loew, Sanofi Executive Vice
President and head of Sanofi Pasteur. "The addition of Flublok Quadrivalent
vaccine represents a very attractive opportunity to complement our influenza
vaccines portfolio."
The acquisition of Protein Sciences fits with Sanofi Pasteur's strategic
initiative to explore non-egg-based influenza vaccine manufacturing
technologies. "This acquisition is consistent with our strategic ambition of
expanding our presence in the respiratory vaccine market, and builds on the
recently announced collaboration on an investigational respiratory syncytial
virus (RSV) monoclonal antibody," added David Loew.
An Innovative Quadrivalent Influenza Vaccine
Protein Sciences has developed the baculovirus expression system technology
(B.E.S.T.) platform for the production of recombinant proteins. On this basis,
they have developed and commercialized Flublok Quadrivalent vaccine, a
recombinant influenza vaccine indicated for active immunization of adults 18
years of age and older against seasonal influenza.
"Older adults are at high risk of severe influenza and its complications, so it
is exciting to see that in a recent clinical study in adults 50 years of age and
older, individuals who received Flublok Quadrivalent vaccine were significantly
less likely to get influenza than those who received a quadrivalent inactivated
influenza vaccine. Specifically, Flublok Quadrivalent vaccine, relative to the
comparator, reduced the incidence of lab-confirmed influenza by 30% in this age
group," said David Loew.
Important Safety Information for Flublok Quadrivalent Vaccine as per US locally
approved labelling
Flublok Quadrivalent vaccine is approved for people 18 and older to prevent
influenza disease. The most common side effects from Flublok Quadrivalent
vaccine are pain and tenderness at the site of injection. Headache, fatigue or
muscle ache may occur. Tell the doctor if you have ever experienced Guillain-
Barré syndrome (severe muscle weakness) or have had a severe allergic reaction
to any component of Flublok vaccine. Vaccination with Flublok Quadrivalent
Vaccine may not protect all individuals.
Please click here for the full US Prescribing Information.
About Protein Sciences
Protein Sciences is a privately held biotech company established in 1983 and
headquartered in Meriden, Connecticut, USA. Protein Sciences' mission is to save
lives and improve health through the creation of innovative vaccines and
biopharmaceuticals. Under the terms of the agreement, Sanofi will make an
upfront payment of $650 million and pay up to $100 million upon achievement of
certain milestones. In July, the acquisition was unanimously approved by the
board of directors of Protein Sciences and a majority of Protein Sciences
shareholders.
About Sanofi Pasteur
Sanofi Pasteur is the world's largest manufacturer of influenza vaccines. In
2016, Sanofi Pasteur confirmed its leadership by completing a production of 200
million doses of seasonal influenza vaccine, i.e. approximately 40% of influenza
vaccines distributed worldwide. Sanofi Pasteur produces vaccines against
seasonal influenza on its four sites: Swiftwater (Pennsylvania, United States),
Val-de-Reuil (France), Ocoyoacac (Mexico City, Mexico) and Shenzhen (China).
About Sanofi
Sanofi, a global healthcare leader, discovers, develops and distributes
therapeutic solutions focused on patients' needs. Sanofi is organized into five
global business units: Diabetes and Cardiovascular, General Medicines and
Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Consumer Healthcare. Sanofi
is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
Sanofi Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private
Securities Litigation Reform Act of 1995, as amended. Forward-looking statements
are statements that are not historical facts. These statements include
projections and estimates and their underlying assumptions, statements regarding
plans, objectives, intentions and expectations with respect to future financial
results, events, operations, services, product development and potential, and
statements regarding future performance. Forward-looking statements are
generally identified by the words "expects", "anticipates", "believes",
"intends", "estimates", "plans" and similar expressions. Although Sanofi's
management believes that the expectations reflected in such forward-looking
statements are reasonable, investors are cautioned that forward-looking
information and statements are subject to various risks and uncertainties, many
of which are difficult to predict and generally beyond the control of Sanofi,
that could cause actual results and developments to differ materially from those
expressed in, or implied or projected by, the forward-looking information and
statements. These risks and uncertainties include among other things, the
uncertainties inherent in research and development, future clinical data and
analysis, including post marketing, decisions by regulatory authorities, such as
the FDA or the EMA, regarding whether and when to approve any drug, device or
biological application that may be filed for any such product candidates as well
as their decisions regarding labelling and other matters that could affect the
availability or commercial potential of such product candidates, the absence of
guarantee that the product candidates if approved will be commercially
successful, the future approval and commercial success of therapeutic
alternatives, Sanofi's ability to benefit from external growth opportunities
and/or obtain regulatory clearances, risks associated with intellectual property
and any related pending or future litigation and the ultimate outcome of such
litigation, trends in exchange rates and prevailing interest rates, volatile
economic conditions, the impact of cost containment initiatives and subsequent
changes thereto, the average number of shares outstanding as well as those
discussed or identified in the public filings with the SEC and the AMF made by
Sanofi, including those listed under "Risk Factors" and "Cautionary Statement
Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for
the year ended December 31, 2016. Other than as required by applicable law,
Sanofi does not undertake any obligation to update or revise any forward-looking
information or statements.
Contacts:
Media Relations Investor Relations
Laurence Bollack George Grofik
Tel. : +33 (0)1 53 77 46 46 Tel.: +33 (0)1 53 77 45 45
mr(at)sanofi.com ir(at)sanofi.com
Press release (PDF):
http://hugin.info/152918/R/2129475/813404.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Sanofi via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 28.08.2017 - 07:00 Uhr
Sprache: Deutsch
News-ID 557897
Anzahl Zeichen: 9556
contact information:
Town:
PARIS
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 272 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Sanofi completes the acquisition of Protein Sciences"
steht unter der journalistisch-redaktionellen Verantwortung von
Sanofi (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
